Suppr超能文献

Spontaneous reduction of prolactinoma post cabergoline withdrawal.

作者信息

Venkatesh Sampath Kumar, Kothari Deepak, Manchanda Smita, Taneja Anil, Kulshreshtha Bindu

机构信息

Department of Endocrinology, Dr. Ram Manohar Lohia Hospital, New Delhi, India.

出版信息

Indian J Endocrinol Metab. 2012 Sep;16(5):833-5. doi: 10.4103/2230-8210.100656.

Abstract

Prolactinomas are common pituitary tumors usually highly responsive to dopamine agonists. Around 70-90% of the prolactinomas exhibit decrease in tumor size, though variably with these agents. Uncommonly, there may be little or no shrinkage in pituitary tumor. In the absence of medical therapy, pituitary apoplexy may also result in tumor shrinkage, albeit rarely. We report here a case showing only modest reduction in prolactinoma with cabergoline given for a period of one and a half years. Surprisingly, this tumor showed a 40% reduction in the tumor size 3 months after cabergoline withdrawal in the absence of clinical or radiological evidence of apoplexy.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4155/3475917/64cae0717ec8/IJEM-16-833-g001.jpg

相似文献

1
Spontaneous reduction of prolactinoma post cabergoline withdrawal.
Indian J Endocrinol Metab. 2012 Sep;16(5):833-5. doi: 10.4103/2230-8210.100656.
3
Pituitary Apoplexy during Treatment of Prolactinoma with Cabergoline.
Asian J Neurosurg. 2018 Jan-Mar;13(1):93-95. doi: 10.4103/1793-5482.181130.
4
5
Dopamine agonists in prolactinomas: when to withdraw?
Pituitary. 2020 Feb;23(1):38-44. doi: 10.1007/s11102-019-00989-1.
6
The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma.
J Pediatr Endocrinol Metab. 2014 Jan;27(1-2):159-63. doi: 10.1515/jpem-2013-0151.
7
IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas.
Pituitary. 2018 Aug;21(4):406-413. doi: 10.1007/s11102-018-0891-5.
8
High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?
Endocrine. 2020 Oct;70(1):143-149. doi: 10.1007/s12020-020-02388-0. Epub 2020 Jun 17.
9
Dopamine agonists and pituitary tumor shrinkage.
Endocr Rev. 1992 May;13(2):220-40. doi: 10.1210/edrv-13-2-220.
10
Hyperprolactinemia/Prolactinomas in the Postmenopausal Period: Challenges in Diagnosis and Management.
Neuroendocrinology. 2019;109(1):28-33. doi: 10.1159/000494725. Epub 2018 Oct 22.

本文引用的文献

1
Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis.
J Clin Endocrinol Metab. 2010 Jan;95(1):43-51. doi: 10.1210/jc.2009-1238. Epub 2009 Oct 30.
2
Management of resistant prolactinomas.
Nat Clin Pract Endocrinol Metab. 2006 Oct;2(10):552-61. doi: 10.1038/ncpendmet0290.
3
Pharmacologic resistance in prolactinoma patients.
Pituitary. 2005;8(1):43-52. doi: 10.1007/s11102-005-5085-2.
4
Treatment of pituitary tumors: dopamine agonists.
Endocrine. 2005 Oct;28(1):101-10. doi: 10.1385/endo:28:1:101.
6
Control of lactotrop proliferation by dopamine: essential role of signaling through D2 receptors and ERKs.
Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14530-5. doi: 10.1073/pnas.222319599. Epub 2002 Oct 21.
9
Clinical management of prolactinomas.
Baillieres Best Pract Res Clin Endocrinol Metab. 1999 Oct;13(3):395-408. doi: 10.1053/beem.1999.0030.
10
Spontaneous shrinking of a macroprolactinoma.
Neurochirurgia (Stuttg). 1993 Jan;36(1):17-9. doi: 10.1055/s-2008-1052285.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验